טוען...
Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function
Sorafenib and cisplatin plus gemcitabine currently represent first-line treatment standards in advanced hepatocellular carcinoma and biliary cancer, respectively. Conventional cytotoxic agents (monotherapy or combination therapy) have demonstrated activity in the second-line setting or in those in w...
שמור ב:
| הוצא לאור ב: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AME Publishing Company
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5401853/ https://ncbi.nlm.nih.gov/pubmed/28480070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.09.17 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|